Lastest Stories by Liam Gibson

This article assesses some obstacles rookie traders encounter when starting and considers several strategies to equip oneself with the best knowledge and resources to position oneself to succeed over...
Over the past 150 years, those who've bought up real estate have seen a handsome return on their capital.
Among the various items on the agenda are several shareholder proposals. 
For investors keen on adding more industrial decarbonization solutions to their portfolios, a new spin-off deal is coming down the pipeline. 
Last year's market may have erased trillions in Americans' wealth, yet stocks remain the second most popular long-term investment.
This diversified, multisector fund with a much smaller pool of holdings than the S&P 500 continues to deliver outsized gains.
Investors hungry for a taste test of this year's restaurant offerings will soon have something to savor.
The S&P 500 may have been up over 5% last month, but there were better returns on offer overseas.
Investment banking giant Morgan Stanley is crashing the exchange-traded fund (ETF) party.
One of the first major biotech deals of the new year is offering investors a big bet on diabetes and obesity treatments.
A new natural gas play is coming to market. 
This week marks the 30th birthday of the first-ever U.S. exchange-traded fund, which ignited a new asset class and brought diversified portfolios to the masses. 
A niche healthcare play is coming to market, offering investors exposure to the animal kingdom.
A profitable renewables developer with a multiyear market-beating track record has joined the initial public offering cue. 
A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market.  The clinical-stage drug maker filed for an initial public offering (IPO)...